DOI: http://dx.doi.org/10.18203/2320-1770.ijrcog20200491

Evaluation of risk of malignancy index in adnexal masses at a tertiary hospital: a prospective study

Ritanjali Behera, Paramita Pradhan, Bharati Misra

Abstract


Background: The discrimination between benign and malignant adnexal masses is important in deciding clinical management and optimal surgical planning. The aim of the study was to evaluate the effectiveness of risk of malignancy index (RMI) to identify cases with high potential of ovarian malignancy at a tertiary hospital.

Methods: This prospective study was conducted over a period of two years from September 2017 to August 2019 at obstetrics and gynecology department of M. K. C. G. Medical College and Hospital, Berhampur. A total case of 130 patients with adnexal masses who underwent surgical treatment were included as histopathological report was taken as gold standard to calculate accuracy of RMI.

Results: Of the total masses, 85 (65.4%) were benign and 45 (34.6%) were malignant. The mean age of patients was 41.03±14 years. The best cut off value for the RMI-3 was 225 with highest area under the ROC curve 87%, sensitivity of 75.55%, specificity of 98.82%, PPV of 97.14%, NPV of 88.42% and an accuracy of 90.76%.

Conclusions: The present study demonstrated that RMI was a reliable method in detecting malignant ovarian tumors. The RMI is a simple and practically applicable tool in preoperative discrimination between benign and malignant adnexal masses in non-specialized gynecologic departments, particularly in developing countries.


Keywords


Adnexal masses, CA-125, Ovarian tumors, Risk of malignancy index

Full Text:

PDF

References


Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCON estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394-424.

Takiar R. Status of Ovarian Cancer in India (2012-2014)”. EC Gynaecol. 2019:358-364.

Holschneider CH, Berek JS. Ovarian cancer: epidemiology, biology, and prognostic factors. Semin Surg Oncol. 2000;19:3-10.

Bristow RE, Tomacruz RS, Armstrong DK, Trimble EL, Montz FJ. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J Clin Oncol. 2002;20(5):1248-59.

Kusnetzoff D, Gnochi D, Damonte C, Sananes C. Differential diagnosis of pelvic masses: usefulness of CA 125, transvaginal sonography and echo-Doppler. Int J Gynecol Cancer. 1998;8:315-21.

Jacobs I, Oram D, Fairbanks J, Turner J, Frost C, Grudzinskas JG. A risk of malignancy index incorporating CA125, ultrasound and menopausal status for the accurate preoperative diagnosis of ovarian cancer. Br J Obstet Gynaecol. 1990;97(10):922-9.

Tingulstad S, Hagen B, Skjeldestad F, Onsrud M, Kiserud T, Halvorsen T, et al. Evaluation of a risk of malignancy index based on serum CA125, ultrasound findings and menopausal status in the preoperative diagnosis of pelvic masses. BJOG Int J Obstet Gynaecol. 1996;103(8):826-31.

Tingulstad S, Hagen B, Skjeldestad F, Halvorsen T, Nustad K. Onsrud M. The risk-of-malignancy index to evaluate potential ovarian cancers in local hospitals. Obstet Gynecol. 1999;93(3):448.

Van den Akker PA, Aalders AL, Snijders MP. Evaluation of the risk malignancy index in daily clinical management of adnexal masses. Gynecol Oncol. 2010;116:384-8.

Yamamoto Y, Yamada R, Oguri H, Maeda N, Fukaya T. Comparison of four malignancy risk indices in the preoperative evaluation of patients with pelvic masses. Eur J Obstet Gynecol Reprod Biol. 2009;144(2):163-7.

Berek JS. Berek and Novak’s Gynecology. 15th ed. Philadelphia: Lippincott Williams and Wilkins; 2012:1359-65.

Karimi-Zarchi M, Mojaver SP, Rouhi M, Hekmatimoghaddam SH, Moghaddam RN, Yazdian-Anari P, et al. Diagnostic value of the risk of malignancy index (RMI) for detection of pelvic malignancies compared with pathology. Elect Phys. 2015;7(7):1505-10.

Dora SK, Dandapat AB, Pande B, Hota JP. A prospective study to evaluate risk malignancy index and its diagnostic implication in patients with suspected ovarian mass. J Ovarian Res. 2017;10:55.

Asharfgangooei T, Rezaeezadeh M. Risk of malignancy index in preoperative evaluation of pelvic masses. Asain Pac J Cancer Prev. 2011;12:1727-30.

Simsek HS, Tokmak A, Ozgu E, Doganay M, Danisman N, Erkaya S, et al. Ole of a risk of malignancy index in clinical approaches to adnexal masses. Asian Pac J Cancer Prev. 2014;15(18):7793-7.

Rao JH. Risk of malignancy index in assessment of pelvic mass. Int J Biomed Res. 2014;5(3):184-6.

Kumari N, Gupta V, Kumari R, Makhija A. Evaluation of risk of malignancy index as a diagnostic tool in cases with adnexal mass. Int J Reprod Contracept Obstet Gynecol. 2016;5(6):1857-61.

Vasudevan JA, Nair V, Sukumaran S. Evaluation of risk of malignancy index in the preoperative assessment of ovarian tumors: study from a tertiary center. Saudi J Health Sci. 2016;5:67-71.

Singhal S, Rajoria L, Mital P, Batar A, Ainani R, Agarwal M, Urmila KC. Risk of malignancy index 4 in preoperative evaluation of patients with ovarian tumours. Int J Reprod Contracept Obstet Gynecol. 2018;7(6):2467-71.

Geomini P, Kruitwagen R, Bremer GL, Cnossen J, Mol BWJ. The accuracy of risk scores in predicting ovarian malignancy: a systematic review. Obstet Gynecol. 2009;113(2):384-94.

Enakpene CA, Omigbodun AO, Goecke TW, Odukogbe AT, Beckmann MW. Preoperative evaluation and triage of women with suspicious adnexal masses using risk of malignancy index. J Obstet Gynaecol Res. 2009;35(1):131-8.